ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

被引：0

作者：

Kiladjian, Jean-Jacques ^{[1
]}

Marin, Francisca Ferrer ^{[2
]}

Al-Ali, Haifa Kathrin ^{[3
]}

Alvarez-Larran, Alberto ^{[4
]}

Beggiato, Eloise ^{[5
]}

Bieniaszewska, Maria ^{[6
]}

Breccia, Massimo ^{[7
]}

Buxhofer-Ausch, Veronika ^{[8
]}

Cerna, Olga ^{[9
,10
]}

Crisan, Ana Manuela ^{[11
]}

Danaila, Catalin ^{[12
]}

De Stefano, Valerio ^{[13
]}

Dohner, Konstanze ^{[14
]}

Empson, Victoria ^{[15
]}

Tybor, Joanna Gora ^{[16
]}

Griesshammer, Martin ^{[17
]}

Grosicki, Sebastian ^{[18
]}

Guglielmelli, Paola ^{[19
]}

Gutierrez Sr, Valentin Garcia ^{[20
]}

Heidel, Florian ^{[21
]}

Illes, Arpad ^{[22
]}

James, Chloe ^{[23
]}

Koschmieder, Steffen ^{[24
]}

Maria-Theresa, Krauth ^{[25
]}

Krejcy, Kurt ^{[15
]}

Lazaroiu, Mihaela Cornelia ^{[26
]}

Mayer, Jiri ^{[27
]}

Nagy, Zsolt ^{[28
]}

Palandri, Francesca ^{[29
]}

Pappa, Vasiliki ^{[30
]}

Reiter, Andreas ^{[31
]}

Sacha, Tomasz ^{[32
]}

Schlager, Stefanie ^{[15
]}

Schmidt, Stefan Ulrich ^{[33
]}

Terpos, Evangelos ^{[34
]}

Tomuleasa, Ciprian ^{[35
]}

Torregrosa, Jose Miguel ^{[36
]}

Unger, Martin ^{[15
]}

Woelfler, Albert ^{[37
]}

Xicoy, Blanca ^{[38
]}

Klade, Christoph ^{[15
]}

机构：

[1] Hop St Louis, Ctr Invest Clin, Paris, France

[2] HU Morales Meseguer, Serv Anat Patol, Murcia, Spain

[3] Univ Med Halle, Krukenberg Canc Ctr Halle, Halle, Germany

[4] Hosp Clin Barcelona, ICMHO, Hematol Dept, Barcelona, Spain

[5] AOU Citta Salute & Sci, SC Clin Pharmacol, Turin, Italy

[6] INFN Torino, Turin, Italy

[7] Univ Clin Ctr, Gdansk, Poland

[8] Sapienza Univ Rome, Rome, Italy

[9] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Hematol, Prague, Czech Republic

[10] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Hematol, Prague, Czech Republic

[11] Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania

[12] Reg Inst Oncol, Dept Clin Hematol, Iasi, Romania

[13] Catholic Univ, Dept Urol, Fdn Policlin Univ A Gemelli IRCCS, Med Sch, Rome, Italy

[14] Univ Hosp Ulm, Dept Radiol, Ulm, Germany

[15] AOP Hlth, Vienna, Austria

[16] Med Univ Lodz, Copernicus Mem Hosp Lodz, Dept Biostat & Translat Med, Dept Hematooncol, Lodz, Poland

[17] Univ Bochum, Univ Clin Hematol Oncol Hemostaseol & Palliat Care, Johannes Wesling Med Ctr Minden, Bochum, Germany

[18] Med Univ Silesia, Fac Hlth Sci Bytom, Dept Hematol & Canc Prevent, Katowice, Poland

[19] Univ Studi Firenze, Florence, Italy

[20] Univ Alcala, Hosp Univ Ramon & Cajal, Dept Urol, Inst Ramon & Cajal Invest Sanitaria IRYCIS, Madrid, Spain

[21] Hannover Med Sch, Dept Hematol, Hemostasis Oncol & Stem Cell Transplantat, Hannover, Germany

[22] Univ Debrecen, Clin Ctr, Debrecen, Hungary

[23] Univ Bordeaux, Biol Cardiovasc Dis, Inserm, UMR1034, Pessac, France

[24] Aachen Bonn Cologne Dusseldorf CIO ABCD, Ctr Integrated Oncol, Aachen, Germany

[25] Med Univ Vienna, Clin Div Hematol & Hemostaseol, Dept Internal Medicine1, Vienna, Austria

[26] Policlin Diagnost Rapid, Brasov, Romania

[27] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic

[28] Semmelwe Egyet, Sportorvostan Tanszek, Budapest, Hungary

[29] Ist Ematol Seragnoli, IRCCS Azienda Ospedaliero Universitaria Bologna, Bologna, Italy

[30] Univ Gen Hosp Attikon, Dept Internal Med & Res Unit 2, Athens, Greece

[31] Univ Med Ctr Mannheim, Dept Hematol & Oncol, Mannheim, Germany

[32] Jagiellonian Univ Hosp Krakow, Krakow, Poland

[33] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Innsbruck, Austria

[34] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[35] Iuliu Hatieganu Univ Med & Pharm, MedFuture Res Ctr Advance Med, Cluj Napoca, Romania

[36] Univ Poitiers, Chu Poitiers, Poitiers, France

[37] Med Univ Graz, Oncol, Graz, Austria

[38] Univ Autonoma Barcelona, Inst Catala Oncol Badalona, Josep Carreras Leukemia Res Inst, Hosp Univ Germans Trias & Pujol, Barcelona, Spain

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199028

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6635 / 6637

页数：3

共 50 条

[41] EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1
Sulkowski, Mark S.
Zeuzem, Stefan
Lawitz, Eric
Grigorescu, Mircea
Tice, Alan D.
Rustgi, Vinod K.
Rodriguez-Torres, Maribel
Lurie, Yoav
Cianciara, Janusz
Bacon, Bruce R.
Bain, Vincent G.
Kryczka, Wieslaw
Pulkstenis, Erik
Subramanian, G. M.
McHutchison, John G.
HEPATOLOGY, 2009, 50 (04) : 333A - 333A
[42] The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply
Kirito, Keita
Shimoda, Kazuya
Takenaka, Katsuto
Qin, Albert
Zagrijtschuk, Oleh
Sato, Toshiaki
Miyachi, Narihisa
Kawase, Hiroaki
Yonezu, Katsuya
Komatsu, Norio
BLOOD, 2020, 136
[43] LONGITUDINAL PROSPECTIVE COMPARISON OF FIBROSURE AND FIBROSCAN IN RELATION TO VIROLOGIC RESPONSE IN A PHASE III STUDY OF ALBINTERFERON ALFA-2B AND RIBAVIRIN IN TREATMENT NAiVE CHC PATIENTS
Patel, Keyur
Friedrich-Rust, Mireen
Torbenson, Michael
Zhu, Yan
Pulkstenis, Erik
Subramanian, G. M.
McHutchison, John G.
Nelson, David R.
Sulkowski, Mark S.
Benhamou, Yves
Zeuzem, Stefan
HEPATOLOGY, 2009, 50 (04) : 811A - 812A
[44] Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
Gisslinger, Heinz
Buxhofer-Ausch, Veronika
Thaler, Josef
Schloegl, Ernst
Gastl, Gunther
Wolf, Dominik
Schalling, Martin
Gisslinger, Bettina
Ban, Sarita
Egle, Alexander
Melchardt, Thomas
Burgstaller, Sonja
Willenbacher, Ella
Krauth, Maria Theresa
Them, Nicole C. C.
Kralovics, Robert
Zoerer, Michael
Ammann-Mwathi, Oliver
Kadlecova, Pavla
Zagrijtschuk, Oleh
Klade, Christoph
Greil, Richard
BLOOD, 2015, 126 (23)
[45] Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia
Kanakura, Yuzuru
Miyakawa, Yoshitaka
Wilde, Paul
Smith, Jonathan
Achenbach, Heinrich
Okamoto, Shinichiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (04) : 353 - 360
[46] Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia
Yuzuru Kanakura
Yoshitaka Miyakawa
Paul Wilde
Jonathan Smith
Heinrich Achenbach
Shinichiro Okamoto
International Journal of Hematology, 2014, 100 : 353 - 360
[47] Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer
Schrijvers, D
Johnson, J
Jiminez, U
Gore, M
Kosmidis, P
Szpirglas, H
Robbins, K
Oliveira, J
Lewensohn, R
Schüller, J
Riviere, A
Arvay, C
Langecker, P
Jacob, H
Cvitkovic, E
Vokes, E
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) : 1054 - 1059
[48] EFFICACY AND SAFETY RESULTS OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN INTERFERON-ALFA TREATMENT NAIVE PATIENTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C
Nelson, D.
Benhamou, Y.
Chuang, W. L.
Lawitz, E.
Flisiak, R.
Rodriguez-Torres, M.
Bain, V.
Patel, K.
Cronin, P. W.
Pulkstenis, E.
Subramanian, G. M.
McHutchison, J. G.
JOURNAL OF HEPATOLOGY, 2009, 50 : S378 - S378
[49] Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
Barbui, Tiziano
Vannucchi, Alessandro M.
De Stefano, Valerio
Masciulli, Arianna
Carobbio, Alessandra
Ghirardi, Arianna
Carioli, Greta
Rossi, Elena
Ciceri, Fabio
Bonifacio, Massimiliano
Iurlo, Alessandra
Palandri, Francesca
Benevolo, Giulia
Pane, Fabrizio
Ricco, Alessandra
Carli, Giuseppe
Caramella, Marianna
Rapezzi, Davide
Musolino, Caterina
Siragusa, Sergio
Rumi, Elisa
Patriarca, Andrea
Cascavilla, Nicola
Mora, Barbara
Cacciola, Emma
Mannarelli, Carmela
Loscocco, Giuseppe Gaetano
Guglielmelli, Paola
Gesullo, Francesca
Betti, Silvia
Lunghi, Francesca
Scaffidi, Luigi
Bucelli, Cristina
Vianelli, Nicola
Bellini, Marta
Finazzi, Maria Chiara
Tognoni, Giovanni
Rambaldi, Alessandro
BLOOD, 2022, 140 : 1797 - 1799
[50] Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera
Yacoub, Abdulraheem
Abu-Zeinah, Ghaith
Qin, Albert
Shih, Weichung Joe
Da'na, Waleed
Tashi, Tsewang
Zagrijtschuk, Oleh
Geller, Robert
Gill, Harinder
BLOOD, 2024, 144 : 6626 - 6627

← 1 2 3 4 5 →